Prognostic significance of CD44v5 expression in human thymic epithelial neoplasms

Annals of Thoracic Surgery

Volumn 76, Issue 1, 2003, Pages 213-218

  Lee, Shih Chun ^b   Harn, Horng Jyh ^b   Lin, Torng Sen ^b   Yeh, Kun Tu ^b   Liu, Yao Chi ^b   Tsai, Chien Sung ^b   Cheng, Yeung Leung ^a  

^a TRI SERVICE GENERAL HOSPITAL   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CD44S ANTIGEN; CD44V ANTIGEN; CD44V6 ANTIGEN; CELL SURFACE PROTEIN; MONOCLONAL ANTIBODY; PROTEIN CD44V 5; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CANCER CELL; CANCER PATIENT; CANCER STAGING; CANCER SURVIVAL; CARCINOMA; CORRELATION ANALYSIS; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MALE; MOLECULE; PRIORITY JOURNAL; PROGNOSIS; PROTEIN ANALYSIS; PROTEIN EXPRESSION; REGRESSION ANALYSIS; STATISTICAL ANALYSIS; STATISTICAL SIGNIFICANCE; THYMOMA; THYMUS CANCER;

ADULT; AGED; ANTIGENS, CD44; BIOPSY, NEEDLE; COHORT STUDIES; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NEOPLASMS, GLANDULAR AND EPITHELIAL; POLYMORPHISM, GENETIC; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODELS; SENSITIVITY AND SPECIFICITY; SURVIVAL ANALYSIS; THYMUS NEOPLASMS; TUMOR MARKERS, BIOLOGICAL;

EID: 0038676361     PISSN: 00034975     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0003-4975(03)00319-9     Document Type: Article

References (24)

1. Aruffo A, Stamenkovic I, Melnick M, Underhill CB, Seed B. CD44 is the principal cell surface receptor for hyaluronate. Cell 1990;61:1303-3.
2. Gunthert U. CD44: a multitude of isoforms with diverse functions. Curr Top Microbiol Immunol 1993;184:47-63.
3. St John T, Meyer J, Idzerda R, Gallatin WM. Expression of CD44 confers a new adhesive phenotype on transfected cells. Cell 1990;60:45-52.
4. Huet S, Groux H, Caillou B, Valentin H, Prieur AM, Bernard A. CD44 contributes to T cell activation. J Immunol 1989;143: 798-801.
5. Goodfellow PN, Banting G, Wiles MV, et al. The gene, MIC4, which controls expression of the antigen defined by monoclonal antibody F10.44.2, is on human chromosome 11. Eur J Immunol 1982;12:659-63.
6. Screaton GR, Bell MV, Jackson DG, Cornelis FB, Gerth U, Bell JI. Genomic structure of DNA encoding the lymphocyte homing receptor CD44 reveals at least 12 alternatively spliced exons. Proc Natl Acad Sci USA 1992;89:12160-4.
7. Tempfer C, Losch A, Heinzl H, et al. Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer. Eur J Cancer 1996;32A:2023-5.
8. Guo YJ, Liu G, Wang X, et al. Potential use of soluble CD44 in serum as indicator of tumor burden and metastasis in patients with gastric or colon cancer. Cancer Res 1994;54: 422-6.
9. Harn HJ, Ho LI, Chang JY, Wu CW, Jiang SY, Lee HS, Lee WH. Differential expression of the human metastasis adhesion molecule CD44V in normal and carcinomatous stomach mucosa of Chinese subjects. Cancer 1995;75:1065-71.
10. Hsieh HF, Yu JC, Ho LI, Chiu SC, Harn HJ. Molecular studies into the role of CD44 variants in metastasis in gastric cancer. Mol Pathol 1999;52:25-8.
11. Kondo K, Miyoshi T, Hino N, et al. High frequency expressions of CD44 standard and variant forms in non-small cell lung cancers, but not in small cell lung cancers. J Surg Oncol 1998;69:128-36.
12. Bottger TC, Youssef V, Dutkowski P, Maschek H, Brenner W, Junginger T. Expression of CD44 variant proteins in adenocarcinoma of Barrett's esophagus and its relation to prognosis. Cancer 1998;83:1074-80.
13. Yokoyama Y, Hiyama E, Murakami Y, Matsuura Y, Yokoyama T. Lack of CD44 variant 6 expression in advanced extrahepatic bile duct/ampullary carcinoma. Cancer 1999;86: 1691-9.
14. Harn HJ, Shen KL, Liu CA, Ho LI, Yang LS, Yueh KC. Hyaluronate binding assay study of transfected CD44 V4-V7 isoforms into the human gastric carcinoma cell line SC-M1. J Pathol 1998;184:291-6.
15. Dadmanesh F, Sekihara T, Rosai J. Histologic typing of thymoma according to the new World Health Organization classification. Chest Surg Clin North Am 2001;11:407-20.
16. Masaoka A, Monden Y, Nakahara K, Tanioka T. Follow-up study of thymomas with special reference to their clinical stages. Cancer 1981;48:2485-92.
17. Levine GD, Rosai J. Thymic hyperplasia and neoplasia: a review of current concepts. Hum Pathol 1978;9:495-515.
18. Okumura M, Ohta M, Tateyama H, et al. The World Health Organization histologic classification system reflects the oncologic behavior of thymoma: a clinical study of 273 patients. Cancer 2002;94:624-32.
19. Okumura M, Miyoshi S, Fujii Y, et al. Clinical and functional significance of WHO classification on human thymic epithelial neoplasms: a study of 146 consecutive tumors. Am J Surg Pathol 2001;25:103-10.
20. Hayashi Y, Ishii N, Obayashi C, et al. Thymoma: tumour type related to expression of epidermal growth factor (EGF), EGF-receptor, p53, v-erb B and ras p21. Virchows Arch 1995;426:43-50.
21. Pan CC, Ho DM, Chen WY, Chiang H, Fahn HJ, Wang LS. Expression of E-cadherin and alpha- and beta-catenins in thymoma. J Pathol 1998;184:207-11.
22. Stamenkovic I, Amiot M, Pesando JM, Seed B. A lymphocyte molecule implicated in lymph node homing is a member of the cartilage link protein family. Cell 1989;56:1057-62.
23. Harn HJ, Lee HS, Ho LI, Lee WH, Ding JH. Selective expression of CD44 messenger RNA splice variants in four high grade human brain tumour cell lines. Biochem Mol Biol Int 1994;33:743-9.
24. Harn HJ, Ho LI, Yu CP, et al. The variant mRNA isoform of human metastasis gene (CD44V) detected in the cell lines of human hepatocellular carcinoma. Biochem Mol Biol Int 1994;32:233-8.